Nkarta (NASDAQ:NKTX) Given New $23.00 Price Target at HC Wainwright

Nkarta (NASDAQ:NKTX - Free Report) had its price target raised by HC Wainwright from $22.00 to $23.00 in a research report report published on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other analysts have also recently issued reports on NKTX. Mizuho reduced their price objective on shares of Nkarta from $31.00 to $25.00 and set a buy rating for the company in a research note on Friday, March 22nd. Canaccord Genuity Group decreased their price target on Nkarta from $16.00 to $15.00 and set a buy rating on the stock in a report on Friday. Raymond James restated an outperform rating and issued a $16.00 price objective (up from $13.00) on shares of Nkarta in a research report on Friday, March 22nd. Finally, Needham & Company LLC reiterated a buy rating and set a $15.00 target price on shares of Nkarta in a research report on Wednesday, April 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and a consensus target price of $17.83.

Nkarta Stock Up 5.3 %

NASDAQ:NKTX traded up $0.33 during mid-day trading on Monday, hitting $6.58. 905,974 shares of the company traded hands, compared to its average volume of 1,751,952. The stock's fifty day moving average price is $9.66 and its 200-day moving average price is $7.37. Nkarta has a one year low of $1.28 and a one year high of $16.24. The firm has a market cap of $325.18 million, a price-to-earnings ratio of -2.74 and a beta of 0.88.

Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.05. Equities analysts predict that Nkarta will post -2.36 EPS for the current year.

Insider Buying and Selling at Nkarta

In other news, Director Simeon George bought 2,000,000 shares of the stock in a transaction dated Wednesday, March 27th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $20,000,000.00. Following the transaction, the director now owns 1,548,341 shares of the company's stock, valued at $15,483,410. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 5.60% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Bourgeon Capital Management LLC bought a new stake in shares of Nkarta in the 4th quarter worth about $30,000. Forefront Analytics LLC lifted its stake in Nkarta by 282.5% in the third quarter. Forefront Analytics LLC now owns 39,657 shares of the company's stock worth $55,000 after purchasing an additional 29,290 shares during the last quarter. Bleakley Financial Group LLC purchased a new position in shares of Nkarta during the fourth quarter valued at approximately $70,000. Simplicity Solutions LLC bought a new position in shares of Nkarta during the fourth quarter valued at approximately $70,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Nkarta in the fourth quarter worth approximately $72,000. Institutional investors own 80.54% of the company's stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.